R3i - The Residual Risk Reduction Initiative

Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
Yes No

Become a member to receive our newsletter
and get unrestricted access to downloadable slidekits...

Now available on demand

February 22, 2024

Recent Advances in Pharmacotherapy of Diabetic Retinopathy in type 2 Diabetes Mellitus: PPARɑ agonists

Diabetic retinopathy is already the leading cause of vision loss among working-age adults, and the global burden is expected to escalate in the future. Peroxisome Proliferator-Activated Receptor Alpha (PPARα) activation not only plays a key role in lipid and glucose metabolism and inflammation, but also multiple mechanisms underlying diabetic retinopathy.
Consequently, PPARα agonists have emerged as promising therapies for the treatment of diabetic retinopathy, as discussed in this webinar.

Chairman: Prof. Michel Hermans (Brussels)
Speaker: Prof. Alberto Zambon (Padova)

Latest R3i Booklet and Slidekit

PCSK9 as Therapeutic Target

This booklet/slidedeck, the second in the series, focuses on evidence from clinical trials with PCSK9-targeted therapeutics.

Elevated LDL cholesterol is established as causal for atherosclerotic cardiovascular disease. Statin treatment, although effective in lowering LDL cholesterol, still leaves an unacceptably high residual cardiovascular risk, underlining the need for additional therapies.

VIEW THE SLIDEKIT

R3i Editorial

12 March 2024

The microvascular-macrovascular interplay: the next target?

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco

To date, cholesterol and inflammation are the main targets for managing residual vascular risk.
Added to this, important findings from cardiovascular outcome trials with novel glucose-lowering therapies, i.e., sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists, prompted a shift in guidelines to incorporate these agents in preventive approaches in patients with type 2 diabetes and atherosclerotic cardiovascular disease or risk factors.
Less well investigated, however, is the interplay of microvascular and cardiovascular disease in residual vascular risk, despite evidence that microvascular dysfunction underlies many manifestations of cardiovascular disease.

Landmark studies

12 March 2024

First in-human trial of novel siRNA for lowering lipoprotein(a)

Lepodisiran, a novel short-interfering RNA (siRNA), reduced lipoprotein(a) [Lp(a)] concentration by 97% at highest single dose with response sustained in the long-term.

Focus on...

12 March 2024

Comorbid microvascular disease in patients with peripheral artery disease: an escalating issue

Using data from over 33 million hospital admissions in the USA, over 25% of patients admitted with peripheral artery disease (PAD) had comorbid microvascular disease. This group was at higher risk of adverse limb and cardiovascular events.

Differentiating SPPARMα and fibrates
(PPARα agonists)

This booklet/slidekit discusses the evidence for the novel SPPARMα agonist, pemafibrate, that differentiates it as a distinct therapeutic class from traditional fibrates.

SSPARMα at the Crossroads of Obesity,
Diabetes and Cardiovascular Diseases

This library discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases, including the latest information on the role of triglyceride-rich lipoproteins and their remnants in residual vascular risk.

PCSK9 and Atherosclerosis

Authors review the discovery and structure of PCSK9, PCSK9 levels in health and disease, PCSK9-drug interactions focusing on statin trials, current approaches to PCSK9 inhibition, and recent results from anti-PCSK9 mAb pre-clinical and clinical trials.

Other Slidekits

The R3i Educational Library also contains numerous commented slides concerning micro and macrovascular residual risk as well as the detailed analysis of the most important clinical studies related to it.

Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease

This booklet provides a critical background to triglyceride-rich lipoproteins and their role in ASCVD, concluding with discussion of the trials.

PCS9 as a therapeutic target
Insights from clinical trials

This booklet/slidedeck, the second in the series, focuses on evidence from clinical trials with PCSK9-targeted therapeutics.

Recent publications

Remnant cholesterol and metabolic disorders

Remnant cholesterol may help to predict liver stiffness in individuals with nonalcoholic fatty liver disease (NAFLD), according to this analysis...

Remnant cholesterol and risk of premature mortality

A high level of serum remnant cholesterol was associated with increased risk of premature mortality and reduced life expectancy, according...

RICO registry: elevated triglycerides and residual risk of recurrent ischaemic events

In this report from the Côte d’Or MI observatory (RICO) registry, elevated triglycerides were common and associated with a risk...

Prediabetes, MACE, and adverse limb events

Results from this study from Taiwan showed that prediabetes was associated with an increased risk of major adverse limb events...

Increasing stroke burden in Asia

Stroke is the primary cause of disability and vascular death worldwide, conferring a high economic burden. Moreover, results from the...

NEW The R3i International Steering Committee Meeting, Marrakech 2023

Reducing vascular complications of type 2 diabetes: New targets, new treatments

▷ Watch all 8 sessions Webcasts

R3i NEW PUBLICATIONS

➤ Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

➤ Residual vascular risk in diabetes: Will the SPPARMα concept hold the key?

➤ SPPARMα – the Lazarus effect

KEEPING UP TO DATE
WITH THE SSPARMα REVOLUTION

NEW MOVIE - Understanding how pemafibrate acts

What's Residual Risk?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative?

The R³i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.

"Accreditation by AACI confirms R3i is to be trusted in the field of Residual Vascular Risk."

The information provided on this website is for educational purposes only and cannot be used for personal medical care. Always seek the advice of a qualified health professional if you have any questions regarding diagnosis and/or management of your specific condition.

Residual Risk Reduction Initiative
Picassoplatz 8
4010 Basel
Switzerland